InflaRx N.V.

NASDAQ:IFRX   3:59:51 PM EDT
4.55
+0.29 (+6.81%)
Products

InflaRx Announces Positive Data From Phase II IXCHANGE Study With Vilobelimab In ANCA-Associated Vasculitis

Published: 11/15/2021 13:34 GMT
InflaRx N.V. (IFRX) - Inflarx Announces Positive Data From Phase Ii Ixchange Study With Vilobelimab in Anca-associated Vasculitis (aav).
Inflarx NV - Use of Vilobelimab Instead of Glucocorticoids Led to a Substantially Lower Observed Glucocorticoid Toxicity.
Inflarx NV - Vilobelimab Demonstrated a Good Safety and Tolerability Profile; Vilobelimab.